Ablynx (ABLYF) to Appoint 3 New Directors and Elect New Chairman
10/8/2013 12:08:59 PM
GHENT, Belgium, 7 October 2013 - Ablynx [Euronext Brussels: ABLX] today announced that Dr Peter Fellner, Dr Bo Jesper Hansen and Dr William Jenkins will be proposed for nomination as Independent Non-Executive Directors at the Company’s forthcoming Extraordinary Meeting of its shareholders to be held on 7 November 2013.
The Company also indicated that it is then the intention of the Board to separate the roles of Chairman and CEO. The Board intends to elect Dr Fellner as Chairman to succeed Dr Moses who will remain Chief Executive Officer. The Company also announced that it is the intention of Dr Stephen Bunting and Mr Denis Lucquin to resign from the Ablynx Board.
Commenting on the Board appointments, Dr Edwin Moses, Chairman and CEO of Ablynx, said: “The strengthening and evolution of our Board and the splitting of the roles of Chairman and CEO represent important steps in Ablynx’s continuing transformation into one of Europe’s leading biotech companies. We are delighted to have attracted someone of Peter Fellner’s reputation and track record in the pharmaceutical sector to serve as the new Chairman of our Company. He will be supported in his new role by the appointments of Bo Jesper Hansen and William Jenkins. William’s strong medical and clinical expertise together with Bo Jesper’s background in business development, medical marketing, orphan diseases and mergers and acquisitions, will be extremely valuable for Ablynx as we continue to develop our product pipeline and seek further partnerships with pharmaceutical partners.
“I have great confidence that the new Board will be instrumental in taking Ablynx to the next level and continuing to build significant value for our shareholders. I would also like to take this opportunity to thank Stephen and Denis for their very important contributions as investors and Directors over the past ten years.”
Dr Peter Fellner
Dr Peter Fellner is currently Chairman of the Board of Consort Medical and Optos. In addition, he serves as Chairman of the biotech companies Vernalis and Biotie Therapies, and is Vice Chairman of Astex Pharmaceuticals which is being acquired by Otsuka Pharmaceuticals for $886 million. He is currently a Director of the global biopharmaceutical company UCB, where he is Chairman of the Science Committee of the Board, and is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of Acambis from 2006 until its acquisition by Sanofi Aventis in 2008, and of Premier Research Group from 2007 to 2008, when it was acquired by a private-equity backed group. He also served as Chairman of Celltech Group from 2003 to July 2004, until its acquisition for €2.3 billion by UCB, having been CEO from 1990 onwards during which he oversaw the Company’s growth from a small research-based company to UK’s largest biotech company. Before joining Celltech, he was CEO of Roche UK from 1986 to 1990.
Dr Bo Jesper Hansen
Dr Bo Jesper Hansen, M.D., PhD, currently serves as Executive Chairman of the Boards of Swedish Orphan Biovitrum and TopoTarget. He is also non-Executive Director of a number of biotech and pharma companies including Orphazyme, Newron Pharmaceuticals, CMC AB, Hyperion Therapeutics and Genspera. Dr Hansen served as CEO and President and as Director to the Board of Swedish Orphan International until the acquisition of Biovitrum, forming Swedish Orphan Biovitrum. He also was Non-Executive Director of Gambro until its acquisition by Baxter, and Zymenex, until its acquisition by Chiesi. He founded Scandinavian Medical Research during which he served as Medical Advisor for Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical.
Dr William Jenkins
William J. Jenkins, M.D., is Principal of William Jenkins Pharma Consulting and has been advising a wide range of pharma and biotech companies, and investment and venture capital firms in the healthcare sector since 1999. Formerly, he was Head of Worldwide Clinical and Regulatory Affairs for Novartis Pharma and held a similar position with Glaxo Group Research Limited. He is currently Senior Independent Director of Consort Medical, an ad hoc member of the Board of Evotec and a member of the Advisory Board of Chiesi Farmaceutici. In addition, he serves as Chairman of the Scientific Advisory Board of Evotec and is a member of the Scientific Advisory Boards of BB Biotech Ventures II and III funds, and until recently Nicholas Piramal India.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Ablynx media relations: Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Help employers find you! Check out all the jobs and post your resume.
comments powered by